What are the side effects of Selpercatinib?

Selpercatinib is an innovative RET inhibitor specifically designed to treat cancers associated with RET gene mutations. By interfering with the signaling pathways of cancer cells, it inhibits the spread and growth of tumors. The drug has shown significant therapeutic effects in clinical applications.

What are the side effects of Selpercatinib?

Selpercatinib may cause some side effects, and below is information on common side effects.

1. Fatigue

Fatigue is a common adverse effect, and patients may feel extremely tired and have a marked decrease in their ability to perform daily activities. To cope with fatigue, patients should take reasonable rest periods, avoid overexertion, and consult their doctor about other management measures if necessary.

2. Rash

Red or itchy patches on the skin may appear during the treatment, affecting the patient's comfort and appearance. Patients should keep their skin clean and dry, and allergy medications or topical creams can be used to relieve the symptoms of the rash.

Is Selpercatinib used in special populations?

For the use of drugs in special populations, the following are relevant recommendations and guidance.

1. Patients with liver injury

For patients with severe hepatic impairment, it is recommended to reduce the dose of the drug, reduce the concentration of the drug in the body, and reduce the potential for adverse effects.

In patients with mild to moderate hepatic impairment, dose adjustment is usually not required and liver function is still closely monitored and appropriate adjustments are made according to the patient's specific situation.

2. Precautions during lactation

This medicine may pose a potential risk to the fetus. It is recommended to refrain from breastfeeding during treatment and for a week after the last dose.

What are the drug interactions of Selpercatinib?

Drug interactions may affect the effectiveness of treatment, and information should be obtained before choosing Selpercatinib therapy.

1. Strong and moderate CYP3A inhibitors

Concomitant use of strong or moderate CYP3A inhibitors increases plasma concentrations of Selpercatinib and may increase the risk of adverse effects, including prolongation of the QTc interval.

If these inhibitors must be used, it is recommended to lower the dose of Selpercatinib, monitor the QT interval more frequently, and detect ECG abnormalities in a timely manner.

2. QT interval prolongation drugs

Selpercatinib may cause QTc interval prolongation. When concomitant use of drugs known to prolong the QT interval is required, the QT interval should be monitored more frequently to identify and address potential problems.

[Warm tips] Pay attention to the possible side effects of the drug and record any abnormal reactions. If discomfort or side effects occur, you should contact your doctor for evaluation and treatment in time.